Objectives: Fibrinogen concentrate increasingly is used to treat coagulopathic bleeding in cardiac surgery although its effectiveness and safety have not been shown. The authors conducted a cohort study to quantify the effects of fibrinogen concentrate on postoperative blood loss and transfusion and the occurrence of adverse clinical events in complex cardiac surgery patients.
C
ARDIAC SURGERY often is complicated by excessive peri-and postoperative bleeding, which commonly is treated with transfusion of allogeneic blood products. However, this is known to be associated with adverse events, significant cost, and early and late mortality. [1] [2] [3] [4] [5] [6] [7] [8] [9] Recently, there has been increasing interest in the use of fibrinogen concentrate in patients with severe coagulopathic bleeding in various types of surgery. [10] [11] [12] [13] [14] [15] [16] Only a few small studies [17] [18] [19] addressed the use of fibrinogen concentrate in cardiac surgery; they reported a reduction in postoperative blood loss and transfusion requirements. Consequently, it is still unknown whether fibrinogen concentrate infusion reduces blood loss in cardiac surgery and to what extent it is able to reduce transfusion of blood products. Furthermore, it is unknown whether the infusion of fibrinogen concentrate results in unintended adverse clinical events.
In this study, the authors evaluated the effect of fibrinogen concentrate in patients who underwent complex cardiac surgery from [2007] [2008] [2009] [2010] . A cohort analysis was used to quantify whether the infusion of fibrinogen concentrate during complex cardiac surgery reduced postoperative blood loss and transfusion. Whether the use of fibrinogen concentrate was associated with the occurrence of clinical adverse events also was investigated.
METHODS
This study was designed as a single-center (Isala Clinics, Zwolle, The Netherlands) cohort analysis using systematically and prospectively collected data. At the Isala Clinics, fibrinogen concentrate (Haemocomplettan P; CSL Behring, Marburg, Germany) became available at the end of 2006. The analyses presented in this article were based on all patients who underwent complex cardiac surgery between January 1, 2007, and December 31, 2010. Complex cardiac surgery was defined as coronary artery bypass graft surgery with valve(s) procedures or aortic surgery (ie, root, ascending, arch, or descending aorta). Patients who received fibrinogen concentrate in the intensive care unit (ICU) and patients who had resternotomy after initial surgery were excluded from the analysis to exclude a surgical source of postoperative bleeding. This study was approved by the institutional medical ethical committee (reference 11.0668, June 16, 2011).
Anesthesia and surgical treatment were performed according to the standard procedures of the Isala Clinics and have been described previously. 20 All patients in this cohort received initial hemostasis management involving the use of conventional procoagulant and antifibrinolytic therapy. Tranexamic acid was administered to all patients at the initiation of cardiopulmonary bypass (CPB) with a dose of 2 g and, after CPB, with a dose of 1 g. If indicated, desmopressin was infused with a dose of 0.3 g/kg toward the end of CPB. During surgery, the transfusion of red blood cell (RBC) concentrate, fresh frozen plasma (FFP), and platelet concentrate was performed according to the following transfusion protocol: when hematocrit during CPB was below 23%, 1 U of RBC concentrate was transfused. One unit of platelet concentrate was administered when the thrombocyte count was below 100 ϫ 10 9 /L. When plasma loss measured with the cell saver and the blood loss was more than 1 L or 2 L, 2 or 4 U of FFP were administered, respectively. In case the initial hemostatic management was not effective and a surgical source of bleeding was excluded, fibrinogen concentrate infusion was considered during surgery. Recombinant factor VIIa was considered if bleeding persisted after intervention with fibrinogen concentrate. Cryoprecipitate was not used during the whole study period.
The primary outcome measure was postoperative blood loss in the ICU, which was measured as chest drain production (expressed in milliliters) from admission to the ICU until removal of the chest drains. The secondary outcome measure was the transfusion of RBC concentrate, FFP, and platelets in the ICU analyzed as dichotomous variables. The authors also investigated the occurrence of major clinical events. Thirty-day mortality was defined as death from any cause within 30 days after the surgical procedure. Myocardial infarction was defined as a myocardial-specific CK-MB value Ն180 U/L (7.5 times upper reference limit) plus a peak CK-MB/creatine kinase ratio Ͼ10% or pathologic new Q waves on a postoperative electrocardiogram. 21 A cerebrovascular accident (CVA) was defined as a new motor or sensory deficit with its origin in the central nervous system or an unexplained coma status lasting longer than 24 hours. Transient ischemic attack (TIA) was defined as a brief episode of neurologic dysfunction resulting from focal temporary cerebral ischemia lasting Ͻ24 hours and not associated with cerebral infarction. Renal insufficiency was considered renal injury and/or acute renal failure defined according to the Second International Consensus Conference of the Acute Dialysis Quality Initiative Group. 22 Total infection was defined as any infection (eg, skin infection, mediastinitis, sternal infection, pulmonary infection, or any other infection) occurring in the postoperative period during the hospital stay. Prolonged ventilation was defined as mechanical ventilation in the ICU for more than 24 hours.
For statistical analysis, the authors estimated the crude effect of fibrinogen concentrate intervention on the primary and secondary outcome variables. Because the primary outcome variable was non-normally distributed, a logarithmic transformation and linear regression analysis using log 10 (ICU blood loss) as the dependent variable and fibrinogen intervention as the single independent variable was performed. The resulting regression coefficients b were back-transformed as 10 b , resulting in an estimate of the ratio of geometric means (RGM) with its associated 95% confidence interval. The RGM can be interpreted as follows: an RGM of 1 (reference value) would indicate that the blood loss in the patients receiving fibrinogen equals the amount of blood loss in the nonfibrinogen concentrate group. Values below 1 indicate that patients with fibrinogen concentrate have less blood loss in the ICU (hence, the intervention is effective), and values above 1 indicate that patients who receive fibrinogen concentrate have more blood loss in the ICU. The dichotomous outcome variables were analyzed using logistic regression analysis. Results are presented as odds ratios (ORs) with the corresponding confidence intervals. In parallel with the RGM, values below 1 indicate that intervention with fibrinogen concentrate is effective. Values above 1 indicate that the outcome occurs more frequently in patients who did receive fibrinogen concentrate.
Because of the nonrandomized design of this study, the association between the infusion of fibrinogen concentrate and each of the outcomes likely was biased by potential confounders. Variables considered as potential confounders were baseline patient characteristics (ie, age, sex, body surface area, and EuroSCORE), procedure-related characteristics (ie, type of surgery [elective, urgent, or emergent], CPB time, and minimal core temperature), and characteristics related to the course of the procedure (ie, total blood loss during surgery, transfusion of FFP and platelets during surgery, use of desmopressin and recombinant FVIIa during surgery, and whether the patients were operated on before or after a new transfusion protocol was put into place in the department). These potential confounders were included in the analysis using propensity score analysis, which was conducted as follows: 3 propensity scores for being treated with fibrinogen concentrate were calculated based on the patient characteristics, procedure-related characteristics, and characteristics related to the actual course of the procedure before fibrinogen concentrate was considered. To calculate these scores, 3 regression models were fit using the previously mentioned variables. Second, the probabilities resulting from these models were included in a multivariable regression analysis with fibrinogen concentrate as the primary independent variable of interest and the 3 propensity scores as additional covariables. This second step was performed for each of the outcome measures.
Although very limited, there were missing data for 1 or more confounders with rates ranging from 0% to 3.3%. Missing values were singly imputed using a regression model approach with the addition of a random error component before conducting the analyses. A p value Ͻ0.05 was considered statistically significant. Analyses were performed using the statistical software SPSS 16.0 (SPSS Inc, Chicago, IL).
RESULTS
Over a period of 4 years (2007-2010), 1,173 patients underwent complex cardiac surgery. Of these patients, 95 (8.1%) had rethoracotomy after the initial surgery. Three other patients were excluded because of the use of recombinant factor VIIa without initial fibrinogen concentrate use. Eventually, 1,075 patients met the inclusion criteria; 264 (25%) received fibrinogen concentrate during surgery (the fibrinogen group), and 811 (75%) patients did not receive fibrinogen concentrate (the no-fibrinogen group [ie, the control group]). Patient characteristics were comparable between the 2 groups except for the EuroSCORE, which was higher in the fibrinogen group (median value ϭ 8 v 7, p Ͻ 0.01, Table 1 ). Regarding the procedural characteristics, the fibrinogen group compared with the control group more frequently had urgent or emergency surgery (8% and 10% v 3% and 2%, respectively; p Ͻ 0.01), a longer cardiopulmonary bypass time (221 v 171 min, p Ͻ 0.01) and aortic occlusion time (133 v 116 min, p Ͻ 0.01), a lower core temperature (28°C v 30°C, p Ͻ 0.01), more blood loss during surgery (2,608 v. 1,383 mL, p Ͻ 0.01), and a higher percentage of patients needing transfusion of blood products during surgery (78% v 47%, p Ͻ 0.01). More patients in the fibrinogen group received desmopressin (67% v 45%, p Ͻ 0.01).
There was more postoperative ICU blood loss in the fibrinogen group compared with the control group (670 v 560 mL, p Ͻ 0.01, Table 2 ). The estimated ratio of geometric means for blood loss in the ICU was 1.13 (1.02-1.25), indicating that the fibrinogen group had 13% more blood loss in the ICU compared with the control group (Table 3) . After adjustment for potential confounders, the fibrinogen group seemed to have 2% more postoperative blood loss in the ICU compared with the control group, with an estimated ratio of geometric means of 1.02 (0.91-1.14), although this was not significant. Regarding the need for transfusion in the ICU, more patients in the fibrinogen group received blood products in the ICU compared with the control group (55% v 43%, p Ͻ 0.01), with an OR of 1.57 (1.19-2.08), which declined to 1.14 (0.83-1.56) in the adjusted analyses (Table 3 ). This means that in the unadjusted analysis 57% more patients in the fibrinogen group (as compared with the control group) received transfusion of a blood product in the ICU. In the adjusted analysis, this figure decreased to 14%; this was not statistically significant.
Prolonged mechanical ventilation (more than 24 hours) was higher in the fibrinogen group (20% v 6%, p Ͻ 0.01), with an OR of 4.18 (2.72-6.40), which declined to 1.44 (0.83-2.49) in the adjusted analysis. The occurrence of 30-day mortality, myocardial infarction, CVA/TIA, renal insufficiency, or failure and infections was not different between the fibrinogen group and the control group in both the unadjusted and adjusted analyses.
DISCUSSION
Fibrinogen concentrate increasingly is used in cardiac surgery procedures complicated by excessive bleeding. In this study, fibrinogen concentrate did not have a statistically significant effect on blood loss and transfusion of blood products in the ICU, and no increased risk in adverse clinical events was found after adjusting for potential confounders.
It is possible that fibrinogen concentrate truly is not effective in patients undergoing complex cardiac surgery. However, the present findings probably can be (partly) explained by the following issues. First, because of the nonrandomized nature of this study, the infusion of fibrinogen concentrate probably was inconsistent and created the potential problem of selective administration of fibrinogen. This is reflected by the differences in the baseline patient and procedure characteristics between the fibrinogen group and the control group. Patients who had a longer CPB time or who had more blood loss and transfusion during surgery were more likely to receive fibrinogen concentrate. To reduce or minimize this effect of confounding by indication, the propensity score method was used for the multivariate regression analysis. To verify the use of the propensity scores for adjustment, the distribution of the propensity scores was investigated by stratifying the propensity score across quintiles. Good overlap was seen within each propensity model concerning patient and procedure characteristics and good overlap in the final model in which all variables and potential confounders were included. As a sensitivity analysis, the authors performed the analyses using other methods for covariable adjustment for the primary outcome of blood loss in the ICU along with variations in the propensity score methodology. These methods all yielded comparable results, confirming the stability of the original findings.
Second, the dose of fibrinogen concentrate seems to be important in reversing coagulopathic bleeding. Fibrinogen concentrate has a dose-dependent effect on platelet aggregation and overall clot strength independent of the platelet count. 23 In the study of Rahe-Meyer et al, 18 a median dose of 7.8 g of fibrinogen concentrate was infused in a study population that is comparable with the present study's cohort. The median dose of fibrinogen concentrate infusion in the present study was relatively low, with 60% of the study population in the fibrinogen group receiving 1 or 2 g of fibrinogen concentrate. These relatively low doses may have attenuated the effect of fibrinogen concentrate on postoperative blood loss.
Third, next to dosing, the timing of infusion might be crucial in coagulation management. In the study of Karlsson et al, 17 fibrinogen was infused on a prophylactic basis in cardiac surgery patients, suggesting that early intervention during coagulation management possibly might result in an improved hemostatic condition. Another example of early treatment is a study by Solomon et al 24 in 39 cardiac surgery patients. These patients received a mean dose of fibrinogen concentrate of 6.5 g as a first-line treatment in coagulopathic bleeding, which resulted in an increase of plasma fibrinogen levels and point-ofcare thromboelastometric variables mirroring fibrinogen polymerization. 24 In the present study, fibrinogen concentrate was infused when a surgical source of bleeding was excluded, (after the removal of CPB) the activated coagulation time was Ͻ140 seconds, the thrombocyte count and hematocrit were corrected, and tranexamic acid and desmopressin therapy were deemed unsuccessful in the treatment of coagulopathic bleeding. This strategy has led to a relatively late intervention with fibrinogen concentrate during coagulation management. Late intervention leads to ongoing, untreated coagulopathic bleeding with wasting of coagulation factors consequently leading to worsening of hemostasis. These factors probably contributed to a reduced hemostatic effect of fibrinogen concentrate therapy. For the occurrence of adverse clinical events in the adjusted analysis, no increase in 30-day mortality, myocardial infarction, CVA/ TIA, renal insufficiency or failure, combined total infections, or prolonged ventilation was measured in the fibrinogen group.
There are limitations to this study. The fibrinogen group had a higher risk for prolonged mechanical ventilation in the unadjusted analysis, which is explained by the longer CPB time and more blood loss and transfusion in this group. These variables indicate that the fibrinogen group is a high-risk group. Although the baseline characteristics between the fibrinogen NOTE. Model 1 ϭ unadjusted analysis; model 2 ϭ model 1 ϩ propensity score of patient characteristics (ie, age, sex, body surface area, and EuroSCORE); model 3 ϭ model 2 ϩ propensity score of procedure characteristics (ie, indication for surgery, cardiac bypass time, and minimal core temperature); and model 4 ϭ model 3 ϩ propensity score of total blood loss surgery, transfusion of FFP, transfusion of platelets, infusion of desmopressin and rFVIIa, and new transfusion protocol. RGM ϭ ratio of geometric mean (10 (␤-coefficient of regression line Ϯ CI) ).
Abbreviations: CI, confidence interval; OR, odds ratio.
group and the control group were different, the propensity score method was used to adjust for these differences. Despite this statistical approach, confounding by unknown or immeasurable factors cannot be ruled out, especially in nonrandomized studies such as the present one. Only a randomized study would counteract these pitfalls. A recently published review by Levy et al 25 gives a complete overview of the current status of fibrinogen concentrate therapy in acquired bleeding states. The authors mention the growing number of studies concerning fibrinogen replacement in the treatment of massive bleeding across a broad range of clinical settings. Most of these studies are retrospective or performed in prospective trials with limited participants. The authors underlined the need for a prospective, randomized controlled trial to determine the role of fibrinogen concentrate in various clinical settings. In addition, this trial would help to define further the optimal trigger concentrations and doses for fibrinogen infusion. 25 It can be concluded that fibrinogen concentrate infusion during complex cardiac surgery did not reduce postoperative blood loss and transfusion. Furthermore, no increase in adverse clinical events was measured. The lack of a clinical effect on blood loss and transfusion might be explained by the low doses and the relatively late intervention with fibrinogen concentrate during coagulation management. Although a randomized clinical trial on the effect of fibrinogen concentrate is lacking to support any recommendation, there is probably much to gain with a higher dose and an earlier fibrinogen concentrate infusion, preferably guided by laboratory plasma concentrations of fibrinogen or thromboelastometry. A randomized, doubleblinded, placebo-controlled trial is needed to answer these very important questions concerning effectiveness, timing, and dosing.
This study only reports the initial clinical use of fibrinogen concentrate in complex cardiac surgery and has methodologic limitations because of its nonrandomized design. Therefore, with the experience gained in the past years and the results of this study, the present authors designed a randomized clinical trial to determine the hemostatic role of fibrinogen concentrate in complex cardiac surgery with a focus on adequate timing and dosing of therapy (http:// ClinicalTrials.gov identifier NCT01124981). 
